These benefits, together with a preceding report displaying that a little-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like behavior in mice,two assist the idea of targeting ACKR3 as a novel approach to modulate the opioid program, which could open up new therapeutic avenues for opioid-asso